TNSN05164A1 - 2-(1h-indazol-6-ylamino)-benzamides en tant qu'inhibiteurs de proteines kinases utiles pour le traitement de maladies ophtalmiques - Google Patents

2-(1h-indazol-6-ylamino)-benzamides en tant qu'inhibiteurs de proteines kinases utiles pour le traitement de maladies ophtalmiques

Info

Publication number: TNSN05164A1
Authority: TN; Tunisia
Prior art keywords: compounds; ophthalmic diseases; inhibitors; protein kinases; benzamides
Prior art date: 2002-12-19

Application number

TNP2005000164A

Other languages

English (en)

French (fr)

Inventor

Robert Steven Kania

Allen John Borchardt

Cynthia Louise Palmer

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-19

Filing date

2005-06-17

Publication date

2007-05-14

2005-06-17 Application filed by Pfizer filed Critical Pfizer

2007-05-14 Publication of TNSN05164A1 publication Critical patent/TNSN05164A1/fr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

TNP2005000164A 2002-12-19 2005-06-17 2-(1h-indazol-6-ylamino)-benzamides en tant qu'inhibiteurs de proteines kinases utiles pour le traitement de maladies ophtalmiques TNSN05164A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US43490202P	2002-12-19	2002-12-19
PCT/IB2003/005854 WO2004056806A1 (en)	2002-12-19	2003-12-08	2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases

Publications (1)

Publication Number	Publication Date
TNSN05164A1 true TNSN05164A1 (fr)	2007-05-14

Family

ID=32682122

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2005000164A TNSN05164A1 (fr)	2002-12-19	2005-06-17	2-(1h-indazol-6-ylamino)-benzamides en tant qu'inhibiteurs de proteines kinases utiles pour le traitement de maladies ophtalmiques

Country Status (37)

Country	Link
US (2)	US7053107B2 (zh)
EP (1)	EP1585743B1 (zh)
JP (1)	JP3814285B2 (zh)
KR (1)	KR100730267B1 (zh)
CN (1)	CN1747950A (zh)
AP (1)	AP2005003341A0 (zh)
AR (1)	AR042510A1 (zh)
AT (1)	ATE362928T1 (zh)
AU (1)	AU2003286321A1 (zh)
BR (1)	BR0317548A (zh)
CA (1)	CA2510850A1 (zh)
CO (1)	CO5580767A2 (zh)
CR (1)	CR7882A (zh)
DE (1)	DE60314013T2 (zh)
DK (1)	DK1585743T3 (zh)
EA (1)	EA008501B1 (zh)
EC (1)	ECSP055858A (zh)
GT (1)	GT200300294A (zh)
HR (1)	HRP20050559A2 (zh)
IS (1)	IS7859A (zh)
MA (1)	MA27570A1 (zh)
MX (1)	MXPA05006676A (zh)
NL (1)	NL1025073C2 (zh)
NO (1)	NO20053486L (zh)
NZ (1)	NZ540340A (zh)
OA (1)	OA12977A (zh)
PA (1)	PA8592901A1 (zh)
PE (1)	PE20041006A1 (zh)
PL (1)	PL377713A1 (zh)
PT (1)	PT1585743E (zh)
RS (1)	RS20050430A (zh)
SI (1)	SI1585743T1 (zh)
TN (1)	TNSN05164A1 (zh)
TW (1)	TW200424193A (zh)
UY (1)	UY28130A1 (zh)
WO (1)	WO2004056806A1 (zh)
ZA (1)	ZA200504339B (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA89035C2 (ru)	2003-12-03	2009-12-25	Лео Фарма А/С	Эфиры гидроксамовых кислот и их фармацевтическое применение
JPWO2005094823A1 (ja) *	2004-03-30	2007-08-16	協和醗酵工業株式会社	Ｆｌｔ−３阻害剤
US20060182783A1 (en) *	2004-04-30	2006-08-17	Allergan, Inc.	Sustained release intraocular drug delivery systems
WO2006043172A1 (en) *	2004-10-19	2006-04-27	Pfizer Inc.	Pharmaceutical compositions and methods for sub-tenon delivery
CA2586176A1 (en) *	2004-11-02	2006-05-11	Srinivasan Babu	Methods for preparing indazole compounds
US20060160863A1 (en) *	2005-01-05	2006-07-20	Agouron Pharmaceuticals, Inc.	Polymorphic and amorphous forms of 2-{3-[(E)-2-(4,6-dimethyl-pyridin-2-yl)-vinyl]-1H-indazol-6-ylamino}-N-(4-hydroxy-but-2-ynyl)benzamide
WO2006117666A2 (en) *	2005-04-29	2006-11-09	Pfizer Inc.	Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
US8340944B2 (en)	2005-11-30	2012-12-25	The Invention Science Fund I, Llc	Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US10296720B2 (en)	2005-11-30	2019-05-21	Gearbox Llc	Computational systems and methods related to nutraceuticals
US7827042B2 (en)	2005-11-30	2010-11-02	The Invention Science Fund I, Inc	Methods and systems related to transmission of nutraceutical associated information
US8297028B2 (en)	2006-06-14	2012-10-30	The Invention Science Fund I, Llc	Individualized pharmaceutical selection and packaging
US8000981B2 (en)	2005-11-30	2011-08-16	The Invention Science Fund I, Llc	Methods and systems related to receiving nutraceutical associated information
US20080103746A1 (en) *	2005-11-30	2008-05-01	Searete Llc, A Limited Liability Corporation	Systems and methods for pathogen detection and response
US7974856B2 (en)	2005-11-30	2011-07-05	The Invention Science Fund I, Llc	Computational systems and methods related to nutraceuticals
US7927787B2 (en)	2006-06-28	2011-04-19	The Invention Science Fund I, Llc	Methods and systems for analysis of nutraceutical associated components
CA2641884A1 (en) *	2006-02-10	2007-08-16	Summit Corporation Plc	Treatment of duchenne muscular dystrophy
WO2008020606A1 (fr) *	2006-08-16	2008-02-21	Kyowa Hakko Kirin Co., Ltd.	Agent anti-angiogénique
CN101677979A (zh) *	2007-04-19	2010-03-24	利奥制药有限公司	Src家族激酶抑制剂
RU2494089C2 (ru)	2007-04-20	2013-09-27	Акьюсела Инк.	Соединения, представляющие собой стиролильные производные, для лечения офтальмических заболеваний и расстройств
US20090081277A1 (en) *	2007-09-21	2009-03-26	Allergan, Inc.	Pharmaceutical formulations and methods for treating ocular conditions
CA2734551A1 (en)	2008-08-27	2010-03-04	Leo Pharma A/S	Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors
CN103804349A (zh) *	2012-11-01	2014-05-21	杨子娇	一类治疗青光眼的化合物及其用途
JO3425B1 (ar)	2013-07-15	2019-10-20	Novartis Ag	مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
JP6407257B2 (ja) *	2014-03-31	2018-10-17	千寿製薬株式会社	アルキニルインダゾール誘導体及びその用途
CN104744338A (zh) *	2015-03-31	2015-07-01	天津维智精细化工有限公司	一种6-氯羟吲哚的合成方法
EP3333157B1 (en) *	2015-08-07	2020-12-23	Harbin Zhenbao Pharmaceutical Co., Ltd.	Vinyl compounds as fgfr and vegfr inhibitors
CN109942544B (zh) *	2017-12-21	2021-06-11	中国科学院合肥物质科学研究院	一类新型吲唑类衍生物激酶抑制剂
WO2024032584A1 (zh) *	2022-08-08	2024-02-15	苏州必扬医药科技有限公司	一种蛋白酪氨酸激酶抑制剂及其医疗用途

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8827305D0 (en)	1988-11-23	1988-12-29	British Bio Technology	Compounds
US5587458A (en)	1991-10-07	1996-12-24	Aronex Pharmaceuticals, Inc.	Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP0625200B1 (en)	1992-02-06	2005-05-11	Chiron Corporation	Biosynthetic binding protein for cancer marker
US5178635A (en)	1992-05-04	1993-01-12	Allergan, Inc.	Method for determining amount of medication in an implantable device
US6177401B1 (en)	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5443505A (en)	1993-11-15	1995-08-22	Oculex Pharmaceuticals, Inc.	Biocompatible ocular implants
IL112248A0 (en)	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
ES2219670T3 (es)	1994-11-10	2004-12-01	Millennium Pharmaceuticals, Inc.	Utilizacion de compuestos de pirazola para el tratamiento de la glomerulonefritis, cancer, ateroesclerosis o restenosis.
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
EP0821671B1 (en)	1995-04-20	2000-12-27	Pfizer Inc.	Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
US5747498A (en)	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en)	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
US5773019A (en)	1995-09-27	1998-06-30	The University Of Kentucky Research Foundation	Implantable controlled release device to deliver drugs directly to an internal portion of the body
GB9520822D0 (en)	1995-10-11	1995-12-13	Wellcome Found	Therapeutically active compounds
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
DK0780386T3 (da)	1995-12-20	2003-02-03	Hoffmann La Roche	Matrixmetalloproteaseinhibitorer
DK0885198T3 (da)	1996-03-05	2002-03-25	Astrazeneca Ab	4-Anilinoquinazolinderivater
EP0888310B1 (en)	1996-03-15	2005-09-07	AstraZeneca AB	Cinnoline derivatives and use as medicine
WO1997049700A1 (en)	1996-06-27	1997-12-31	Pfizer Inc.	Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
EP0818442A3 (en)	1996-07-12	1998-12-30	Pfizer Inc.	Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
DE69718472T2 (de)	1996-07-13	2003-11-06	Glaxo Group Ltd	Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
AR007857A1 (es)	1996-07-13	1999-11-24	Glaxo Group Ltd	Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
HRP970371A2 (en)	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
EP0923585B1 (en)	1996-07-18	2002-05-08	Pfizer Inc.	Phosphinate based inhibitors of matrix metalloproteases
JP2000501423A (ja)	1996-08-23	2000-02-08	ファイザーインク．	アリールスルホニルアミノヒドロキサム酸誘導体
ID18494A (id)	1996-10-02	1998-04-16	Novartis Ag	Turunan pirazola leburan dan proses pembuatannya
PT950059E (pt)	1997-01-06	2004-10-29	Pfizer	Derivados de sulfona ciclicos
ID22799A (id)	1997-02-03	1999-12-09	Pfizer Prod Inc	Turunan-turunan asam arilsulfonilamino hidroksamat
JP2000507975A (ja)	1997-02-07	2000-06-27	ファイザー・インク	Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
IL131123A0 (en)	1997-02-11	2001-01-28	Pfizer	Arylsulfonyl hydroxamic acid derivatives
CA2289102A1 (en)	1997-05-07	1998-11-12	Sugen, Inc.	2-indolinone derivatives as modulators of protein kinase activity
AU734009B2 (en)	1997-05-30	2001-05-31	Merck & Co., Inc.	Novel angiogenesis inhibitors
US6658447B2 (en) *	1997-07-08	2003-12-02	Intel Corporation	Priority based simultaneous multi-threading
US6214872B1 (en)	1997-08-08	2001-04-10	Pfizer Inc.	Aryloxyarylsulfonylamino hydroxamic acid derivatives
EP1005470B1 (en)	1997-08-22	2007-08-01	AstraZeneca AB	Oxindolylquinazoline derivatives as angiogenesis inhibitors
AU744939B2 (en)	1997-09-26	2002-03-07	Merck & Co., Inc.	Novel angiogenesis inhibitors
EP1028964A1 (en)	1997-11-11	2000-08-23	Pfizer Products Inc.	Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en)	1997-12-05	1998-02-04	Pfizer Ltd	Therapeutic agents
JPH11236333A (ja)	1997-12-30	1999-08-31	Pfizer Prod Inc	抗ガン剤として有用なイミダゾリン−４−オン誘導体
GB9800569D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
GB9800575D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
GB9801690D0 (en)	1998-01-27	1998-03-25	Pfizer Ltd	Therapeutic agents
PA8469501A1 (es)	1998-04-10	2000-09-29	Pfizer Prod Inc	Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es)	1998-04-10	2000-05-24	Pfizer Prod Inc	Derivados biciclicos del acido hidroxamico
DK2020408T3 (da)	1998-05-29	2013-09-30	Sugen Inc	Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor
UA60365C2 (uk)	1998-06-04	2003-10-15	Пфайзер Продактс Інк.	Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
NZ509372A (en)	1998-08-27	2003-08-29	Pfizer Prod Inc	Substituted quinolin-2-one derivatives, pharmaceuticals thereof and their use for treating abnormal cell growth (e.g. cancer)
BR9913315A (pt)	1998-08-27	2001-05-22	Pfizer Prod Inc	Derivados de quinolin-2-ona úteis como agentes anticâncer
US6114361A (en)	1998-11-05	2000-09-05	Pfizer Inc.	5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
EP1006113A1 (en)	1998-12-02	2000-06-07	Pfizer Products Inc.	Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
US6649645B1 (en)	1998-12-23	2003-11-18	Pharmacia Corporation	Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
EE05627B1 (et)	1998-12-23	2013-02-15	Pfizer Inc.	CTLA-4 vastased inimese monoklonaalsed antikehad
KR20010109275A (ko)	1998-12-23	2001-12-08	로저 에이. 윌리암스	종양치료의 병용치료로서 사이클로옥시게나제-2 억제제와기질 금속단백분해효소 억제제를 사용하는 방법
UA71945C2 (en)	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja)	1999-01-27	2002-04-02	ファイザー・プロダクツ・インク	抗がん剤として有用なヘテロ芳香族二環式誘導体
TR200201297T2 (tr)	1999-02-11	2002-06-21	Pfizer Products Inc.	Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri.
US6586447B1 (en)	1999-04-01	2003-07-01	Pfizer Inc	3,3-disubstituted-oxindole derivatives useful as anticancer agents
US6511993B1 (en)	1999-06-03	2003-01-28	Kevin Neil Dack	Metalloprotease inhibitors
TWI262914B (en) *	1999-07-02	2006-10-01	Agouron Pharma	Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) *	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
EP1081137A1 (en)	1999-08-12	2001-03-07	Pfizer Products Inc.	Selective inhibitors of aggrecanase in osteoarthritis treatment
JP2001121829A (ja) *	1999-10-26	2001-05-08	Sony Chem Corp	情報記録用シート
ES2212971T3 (es)	1999-11-30	2004-08-16	Pfizer Products Inc.	Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa.
UA75055C2 (uk)	1999-11-30	2006-03-15	Пфайзер Продактс Інк.	Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
YU54202A (sh) *	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2000000266A (es)	2000-01-21	2001-05-21	Pfizer Prod Inc	Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
US6844357B2 (en)	2000-05-01	2005-01-18	Pfizer Inc.	Substituted quinolin-2-one derivatives useful as antiproliferative agents
AR038957A1 (es)	2001-08-15	2005-02-02	Pharmacia Corp	Terapia de combinacion para el tratamiento del cancer

2003
- 2003-12-08 NZ NZ540340A patent/NZ540340A/en unknown
- 2003-12-08 AU AU2003286321A patent/AU2003286321A1/en not_active Abandoned
- 2003-12-08 SI SI200330833T patent/SI1585743T1/sl unknown
- 2003-12-08 WO PCT/IB2003/005854 patent/WO2004056806A1/en active IP Right Grant
- 2003-12-08 BR BR0317548-0A patent/BR0317548A/pt not_active IP Right Cessation
- 2003-12-08 PL PL377713A patent/PL377713A1/pl not_active Application Discontinuation
- 2003-12-08 AP AP2005003341A patent/AP2005003341A0/xx unknown
- 2003-12-08 CN CNA2003801096976A patent/CN1747950A/zh active Pending
- 2003-12-08 JP JP2004561821A patent/JP3814285B2/ja not_active Expired - Fee Related
- 2003-12-08 OA OA1200500188A patent/OA12977A/en unknown
- 2003-12-08 DK DK03777064T patent/DK1585743T3/da active
- 2003-12-08 CA CA002510850A patent/CA2510850A1/en not_active Abandoned
- 2003-12-08 KR KR1020057011551A patent/KR100730267B1/ko not_active IP Right Cessation
- 2003-12-08 EA EA200500811A patent/EA008501B1/ru not_active IP Right Cessation
- 2003-12-08 AT AT03777064T patent/ATE362928T1/de not_active IP Right Cessation
- 2003-12-08 RS YUP-2005/0430A patent/RS20050430A/sr unknown
- 2003-12-08 MX MXPA05006676A patent/MXPA05006676A/es unknown
- 2003-12-08 DE DE60314013T patent/DE60314013T2/de not_active Expired - Fee Related
- 2003-12-08 EP EP03777064A patent/EP1585743B1/en not_active Expired - Lifetime
- 2003-12-08 PT PT03777064T patent/PT1585743E/pt unknown
- 2003-12-11 PE PE2003001269A patent/PE20041006A1/es not_active Application Discontinuation
- 2003-12-15 US US10/737,655 patent/US7053107B2/en not_active Expired - Fee Related
- 2003-12-17 PA PA20038592901A patent/PA8592901A1/es unknown
- 2003-12-17 AR ARP030104683A patent/AR042510A1/es unknown
- 2003-12-17 UY UY28130A patent/UY28130A1/es not_active Application Discontinuation
- 2003-12-18 NL NL1025073A patent/NL1025073C2/nl not_active IP Right Cessation
- 2003-12-18 GT GT200300294A patent/GT200300294A/es unknown
- 2003-12-18 TW TW092135955A patent/TW200424193A/zh unknown
2005
- 2005-05-23 IS IS7859A patent/IS7859A/is unknown
- 2005-05-27 ZA ZA200504339A patent/ZA200504339B/en unknown
- 2005-06-15 EC EC2005005858A patent/ECSP055858A/es unknown
- 2005-06-16 HR HR20050559A patent/HRP20050559A2/hr not_active Application Discontinuation
- 2005-06-17 CO CO05059483A patent/CO5580767A2/es not_active Application Discontinuation
- 2005-06-17 MA MA28348A patent/MA27570A1/fr unknown
- 2005-06-17 TN TNP2005000164A patent/TNSN05164A1/fr unknown
- 2005-06-17 CR CR7882A patent/CR7882A/es not_active Application Discontinuation
- 2005-07-18 NO NO20053486A patent/NO20053486L/no not_active Application Discontinuation
- 2005-12-16 US US11/305,811 patent/US20060160858A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2004056806A1 (en)	2004-07-08
KR20050084439A (ko)	2005-08-26
US7053107B2 (en)	2006-05-30
CR7882A (es)	2005-08-05
DE60314013D1 (de)	2007-07-05
EP1585743B1 (en)	2007-05-23
DE60314013T2 (de)	2008-01-17
TW200424193A (en)	2004-11-16
EA008501B1 (ru)	2007-06-29
DK1585743T3 (da)	2007-09-17
SI1585743T1 (sl)	2007-08-31
US20040192735A1 (en)	2004-09-30
HRP20050559A2 (en)	2006-02-28
ECSP055858A (es)	2005-09-20
JP3814285B2 (ja)	2006-08-23
NZ540340A (en)	2007-07-27
EP1585743A1 (en)	2005-10-19
EA200500811A1 (ru)	2005-12-29
PE20041006A1 (es)	2004-12-24
IS7859A (is)	2005-05-23
CN1747950A (zh)	2006-03-15
MA27570A1 (fr)	2005-10-03
PA8592901A1 (es)	2005-02-04
JP2006515589A (ja)	2006-06-01
AU2003286321A1 (en)	2004-07-14
US20060160858A1 (en)	2006-07-20
NO20053486L (no)	2005-07-18
AP2005003341A0 (en)	2005-06-30
CO5580767A2 (es)	2005-11-30
NL1025073C2 (nl)	2005-02-01
OA12977A (en)	2006-10-13
NL1025073A1 (nl)	2004-06-22
RS20050430A (en)	2007-08-03
PL377713A1 (pl)	2006-02-06
ATE362928T1 (de)	2007-06-15
ZA200504339B (en)	2006-07-26
AR042510A1 (es)	2005-06-22
MXPA05006676A (es)	2005-08-16
CA2510850A1 (en)	2004-07-08
KR100730267B1 (ko)	2007-06-20
BR0317548A (pt)	2005-11-22
GT200300294A (es)	2004-07-27
PT1585743E (pt)	2007-07-12
UY28130A1 (es)	2004-07-30

Publication	Publication Date	Title
TNSN05164A1 (fr)	2007-05-14	2-(1h-indazol-6-ylamino)-benzamides en tant qu'inhibiteurs de proteines kinases utiles pour le traitement de maladies ophtalmiques
EA200200768A1 (ru)	2003-02-27	Соединения индазола, фармацевтические композиции и методы модуляции или ингибирования клеточной пролиферации
MA27937A1 (fr)	2006-06-01	Dérivés d'indazole 3, 5-disubstitués, compositions pharmaceutiques, et méthodes de médiation ou d'inhibition de la prolifération cellulaire
JO2319B1 (en)	2005-09-12	Andazole compounds and pharmaceutical ingredients to inhibit the action of protein enzymes and methods of use
TWI262914B (en)	2006-10-01	Compounds and pharmaceutical compositions for inhibiting protein kinases
Truss et al.	2001	Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside
Tomlinson et al.	2020	The role of nerves in skeletal development, adaptation, and aging
ATE556060T1 (de)	2012-05-15	Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
MA31862B1 (fr)	2010-11-01	Anticorps anti-mésothéline et leurs utilisations
MA27728A1 (fr)	2006-01-02	Antagonistes des recepteurs de cgrp
EA200400488A1 (ru)	2004-10-28	Бензамид и гетероариламид в качестве антагонистов рецептора p2x
ATE509019T1 (de)	2011-05-15	Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten
MA27156A1 (fr)	2005-01-03	NUCLEOSIDES 3- β-D-RIBOFURANOSYLTHIAZOLO[4,5-d] PYRIDIMINE ET LES UTILISATIONS DE CELLES-CI
EP1613368A4 (en)	2008-06-18	Carboxamide-spiro hydantoin-CGRP Receptor Antagonists
YU85601A (sh)	2004-09-03	Diaminotiazoli i njihova upotreba za inhibiranje proteinskih kinaza
MA27311A1 (fr)	2005-05-02	Utilisation d'inhibiteurs de cetp et facultativement d'inhibiteurs de hmg-coa-reductase et/ou d'agents antihypertensifs
MA28429B1 (fr)	2007-02-01	Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases
MA30413B1 (fr)	2009-05-04	Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation
MXPA03001189A (es)	2004-05-14	Compuestos de pirazol-tiazol, composiciones farmaceuticas que los contienen y su uso para inhibir las cinasas dependientes de ciclinas.
Liao et al.	2023	Transient receptor potential vanilloid 1: A potential therapeutic target for the treatment of osteoarthritis and rheumatoid arthritis
Ramana	2010	Tumor necrosis factor-alpha converting enzyme: Implications for ocular inflammatory diseases
NO20044698L (no)	2004-10-29	Statinterapi for a oke kognitiv opprettholdelse
DOP2003000788A (es)	2004-06-30	Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso
DOP2004000953A (es)	2005-01-31	Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular.